Just days after he was born, baby KJ’s future looked heartbreaking.

Doctors discovered that the newborn had CPS1 deficiency, an extremely rare genetic disorder affecting about one in 1.3 million babies. The condition prevents the body from removing toxic ammonia from the bloodstream and is often fatal during the first weeks of life. Even if children survive, many face severe developmental challenges and may eventually require a liver transplant.

Faced with the devastating diagnosis, KJ’s parents, Kyle and Nicole Muldoon, were offered comfort care instead of aggressive treatment.

But they refused to give up on their son.

Instead, doctors at the Children’s Hospital of Philadelphia pursued an extraordinary idea: creating a personalized gene-editing therapy designed specifically for KJ’s unique genetic mutation.

At just a few months old, KJ became the first person in the world to receive a custom-made gene-editing treatment tailored to a single patient’s DNA.

The groundbreaking therapy successfully targeted the mutation responsible for his disease, giving KJ a chance that had never before been possible.

Now 9½ months old, KJ is making remarkable progress, and his case is being hailed as a historic milestone in medicine. Researchers believe this breakthrough could open the door to personalized treatments for thousands of rare genetic disorders—and one day even help treat more common inherited diseases such as sickle cell disease, cystic fibrosis, Huntington’s disease, and muscular dystrophy.

For KJ’s parents, the decision to keep fighting gave their son the opportunity to become part of medical history—and offered new hope to countless other families facing rare genetic diseases.

Source:  THE STRAITS TIMES